The Role of Cell-Free DNA as a Prognostic Marker in Diffuse Large B Cell Lymphoma with Hepatitis C | ||||
| Egyptian Journal of Chemistry | ||||
| Volume 67, Issue 13, December 2024, Page 837-846 PDF (789.33 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejchem.2024.314392.10237 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Samar E. Ghanem1; Hagar A. Alagizy2; Salah M. Elkosy3; Ahmed A. Elgendy  3; Rania M. Afify4; Ashraf A. Basuni1; Shimaa K. Almahdy5
| ||||
| 1Department of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Shebeen El‑Kom, Menoufia, Egypt. | ||||
| 2Depatment of Clinical Oncology, Faculty of Medicine, Menoufia University, Shebeen El‑Kom, Menoufia, Egypt | ||||
| 3Department of Chemistry, Faculty of Science, Menoufia University, Shebeen El‑Kom, Menoufia, Egypt | ||||
| 4Department of Hematology and Internal Medicine, Faculty of Medicine, Helwan University, Helwan, Cairo, Egypt | ||||
| 5Depatment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, ShebeenEl‑Kom, Menoufia, Egypt. | ||||
| Abstract | ||||
| Hepatitis C infection was a serious problem. Over 50 million individuals were successfully screened, and 4 million people were treated. Hepatitis C Virus (HCV) also affects lymphocytes, which explains why non-Hodgkin lymphoma, primarily diffuse large B cell lymphoma (DLBCL), often accompanies HCV infection. Direct Acting Antivirals (DAAs) treatment of HCV has dramatically resolved this problem, but there has been debate about its relationship to the accompanying lymphoma. Cell-free DNA (cfDNA) is a reliable non-invasive biomarker for multiple malignancies, primarily lymphoma. It can aid in prognosis and drug-tailored treatment plans, especially with HCV and DAAs. Objective: This study aimed to evaluate cfDNA as a prognostic biomarker for DLBCL patients. Method: The study was conducted on three groups of subjects: Group 1: DLBCL patients positive for HCV, this group was subdivided to: Group (1A): DLBCL patients positive for HCV [receiving DAAs].Group (1B): DLBCL patients positive HCV [did not receive any treatment for HCV]. Group 2: DLBCL patients negative HCV. Group 3: Control group. All participants underwent full history, clinical examination, routine laboratory investigations and quantitative measurement of cfDNA by real-time PCR. Results: Our study reveals that cfDNA levels are significantly higher in DLBCL patients positive for HCV who did not receive any treatment for HCV (Group 1B), as well as in advanced lymphoma stages. Additionally, we found a high mortality rate among patients with elevated cfDNA. These findings highlight the complex relationship between DLBCL, HCV, and DAA treatment, emphasizing the need for tailored management strategies and increased surveillance in this patient population. Conclusion: cfDNA has a valuable prognostic and monitoring role in DLBCL, particularly with HCV infection. | ||||
| Keywords | ||||
| Cell-free DNA; Diffuse Large B-Cell Lymphoma; Hepatitis C Virus; Direct Acting Antivirals | ||||
|
Statistics Article View: 227 PDF Download: 314 |
||||
